What Is Retatrutide?

Retatrutide is an experimental molecule designed to switch on the receptors for three hormones at once: GIP and GLP-1, the two gut hormones tirzepatide copies, plus a third called glucagon. It is investigational, which means it is still being tested and is not approved as a medicine anywhere. Its main late-stage trials reported in 2026, and its developer has said it plans to apply to the US regulator in early 2027 45.

Our page on tirzepatide explains how one molecule was built to copy two hormones. This page adds the third, and then spends real time on a question people ask constantly: if it has passed Phase 3, why is it not approved? The answer tells you a lot about how medicines get from a laboratory to a pharmacy.

What is glucagon, and why would anyone add it?

Glucagon is a hormone made by the pancreas, the organ behind your stomach that also makes insulin. The two are opposites. Insulin moves sugar out of the blood after a meal. Glucagon does the reverse: between meals and overnight, it tells the liver to release stored sugar back into the blood so that levels do not fall too low. If insulin is the body's way of putting food into the cupboard, glucagon is the way of taking it back out.

So at first sight, copying glucagon in a molecule meant to help with blood sugar and body weight sounds backwards. Why switch on the hormone that pushes blood sugar up?

The reason is that glucagon does more than release sugar. It also pushes the liver towards burning fat, and in studies it appears to raise the amount of energy the body uses 1. The designers' idea was to get those effects while letting the other two hormones, which encourage insulin release, hold the sugar-raising part in check. Picture a team of three pulling a cart. One of them tends to pull slightly off to one side. The other two keep the cart on the road, and all three together pull it further than any one could alone.

Whether that picture holds up fully in people is exactly what the trials were for. The early work showed the balance could be struck without blood sugar rising, which was the first thing that had to be true 13.

How is the molecule built?

It follows the same pattern as tirzepatide. A single chain of amino acids, the building blocks of proteins, was tuned so that it fits three related receptors. A receptor is a structure on the surface of a cell shaped to catch one particular molecule, and these three are close cousins, which is what makes a three-in-one molecule possible at all 1.

Like its relatives, it carries a fatty tail that lets it hold on loosely to albumin, the most common protein in blood. That keeps it from being filtered out by the kidneys and makes it last about six days, long enough for once-weekly use 1. And like tirzepatide, it is deliberately unbalanced. In laboratory tests it acts more strongly at the GIP receptor than natural GIP does, and less strongly at the GLP-1 and glucagon receptors than the natural hormones do 1. The balance is part of the design, not an accident.

Why go to the trouble of three receptors rather than simply pushing harder on one? Because each receptor sits in different tissues and does different work, and pushing any single one too hard has a price. With GLP-1-based medicines, the stomach effects, such as nausea, are the main thing that limits how far the signal can be turned up. Spreading the work across three receptors is an attempt to get more total effect without leaning too heavily on any one of them 1. Think of three people each carrying a third of a heavy box, rather than one person trying to carry all of it. Whether that division of labour really delivers more with fewer problems is one of the questions the late-stage trials were designed to answer.

What does "investigational" mean?

Investigational is the word for a substance that is being tested in people but has not been approved as a medicine. Its developer describes retatrutide exactly that way, and says it is available only inside clinical trials 4. A clinical trial is a planned study in people, run under an agreed plan and watched by ethics committees and regulators.

That is not a comment on whether it works. Plenty of excellent medicines were investigational for years. It is a statement about where it sits in the process. Nobody outside a trial can be given it as a medicine, because no regulator has yet looked at the full evidence and said yes.

What does Phase 3 mean, for this molecule?

Human testing happens in numbered stages. Our page on clinical trials describes them in general. Here is how they have played out for retatrutide.

The first stage checked whether people could tolerate it and how long it lasted in the body 1. The second stage, Phase 2, asked whether it looked worth pursuing. One Phase 2 trial enrolled a few hundred adults with obesity for forty-eight weeks and compared several strengths against a placebo, an inactive look-alike 2. Another did the same in people with type 2 diabetes 3. Both results were strong enough to justify the expense of the next stage.

Phase 3 is the large, late stage, and it is the evidence a regulator actually decides on. For retatrutide it is a group of trials called TRIUMPH. The first to report, TRIUMPH-1, enrolled 2,339 adults with obesity or overweight and at least one weight-related health problem, without diabetes. They were assigned by chance to one of three strengths or to placebo, and followed for eighty weeks 4. The average body-weight change in the higher arms was roughly a quarter of starting weight, against a few percent on placebo 4.

You may see two different sets of figures quoted for that trial, and both are genuine. One counts everybody in the group they were assigned to, including people who stopped early. The other estimates what happened among people who kept going as planned. The second is always the larger number. Neither is a trick, but it is worth knowing which one you are reading, because headlines tend to pick the bigger one.

The trial also recorded what went wrong. Nausea, diarrhoea, constipation and vomiting were all more common than on placebo, and more people in the highest arm stopped because of side effects: about eleven percent, against about five percent on placebo 4. Two further Phase 3 trials, in people with type 2 diabetes and in people with heart disease, reported in July 2026 5.

If Phase 3 is done, why is it not approved?

Because finishing the trials is only the end of one road. Approval needs three more things to happen.

1. The developer puts together an application. This is enormous. It holds every trial result, but also detailed evidence of how the medicine is manufactured, tested and kept stable, batch after batch.
2. The regulator reviews it. Reviewers go through the data independently, can ask questions, and can request more information. This usually takes many months.
3. The regulator decides. It can approve the product for a specific use, ask for more evidence, or refuse.

For retatrutide, the first of those steps is not finished. In July 2026 its developer said it now expects to submit its US application in the first quarter of 2027, later than it had earlier aimed for, because it needs more time to gather manufacturing and quality-control data 5.

That detail is worth pausing on. The molecule's trial results were already known. The delay was about the product: proving that every batch will be made the same way, to the same standard. An approval does not cover a chemical structure in the abstract. It covers a specific product made in a specific way. That is why manufacturing is not paperwork. It is part of what is being approved.

And watching does not stop at approval. A separate long trial is already under way to see whether retatrutide changes the rate of heart and kidney problems over years, which is a different and harder question than body-weight change 6.

What retatrutide is not

• It is not an approved medicine, anywhere, as of September 2026.
• It is not a finished story. Its long-term heart and kidney trial has not reported.
• It is not simply tirzepatide with something added. It is its own molecule with its own balance across three receptors.
• It is not what is sold under its name outside trials. No such material has been tested in any study or assessed by any regulator.

That last point matters more for retatrutide than for the approved molecules on this site, because public interest has run well ahead of the approval process and demand for unapproved material has followed 5. Every result described above came from a trial product, made to a defined standard and given under close supervision. None of it describes anything else.

The short version

Retatrutide is one molecule shaped to switch on three hormone receptors, including glucagon, a hormone you might expect to be left out. Its large trials have reported, and they were strong. It is still not a medicine, because the application has not been filed and no regulator has reviewed it.

The general lesson travels well. "Positive Phase 3 results" and "approved" are different sentences. The gap between them is filled by an application, a review, and a decision about a specific product, and that gap is where many people get ahead of the facts.